Tempo Therapeutics has secured $12m in a Series A financing round to advance its synthetic tissue scaffold products into clinical trials.

The financing round was led by Galaxy Sirius Partners and Johnson & Johnson Innovation – JJDC (JJDC).

This funding will enable the advancement of Tempo’s microporous-annealed-particle (MAP) technology platform.

The MAP technology is a volumetric injectable porous scaffolding for regenerative medicine.

With this technology, Tempo will be able to repurpose established hydrogel polymer components with safety profiles by gathering them into a hyper-porous, flowable scaffold format.

The MAP technology harnesses the power of immune polarisation to rapidly build new tissue in damaged areas, enabling functional regain in critical organs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Galaxy Partners’ Steven Sands and a JJDC representative will join Tempo’s board as part of the financing agreement.

Galaxy Sirius Partners official Marty Sands said: “Tempo is at the forefront of transforming medical outcomes through a genuine regenerative medical technology breakthrough.

“Tempo has a platform patented technology that can meaningfully alter the medical outcomes of a significant amount of surgical procedures.”

Tempo’s two lead products, TT101 and TT108, are poised to enter clinical trials. TT101 is targeted for use in complex surgical sites with exposed bone, fascia or tendon while TT108 is intended for fascial incision site reinforcement.

The Series A funding will be instrumental in establishing the safety and effectiveness of these tissue scaffold candidates.

Steven Sands said: “Tempo Therapeutics might be one of the very few platform technologies that, if it is proven to work on humans, can be used in a myriad of surgical procedures and therapeutic areas.

“This could positively alter patient outcomes across the widest scope of procedures and indications I have ever seen.

“With a strong set of compelling, clinically relevant animal testing in hand, this round allows Tempo to enter the clinic to generate critical and valuable data.”